The global endocrine testing market size reached US$ 11.2 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 20.7 Billion by 2032, exhibiting a growth rate (CAGR) of 7.06% during 2023-2032.
Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient.
The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth.
Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients.
Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further.
Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient.
The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth.
Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients.
Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global endocrine testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type, technology, and end use.Breakup by Test Type:
- Thyroid Test
- Insulin Test
- Human Chorionic Gonadotropin Test
- Prolactin Test
- Luteinizing Hormone Test
- Progesterone Test
- Others
Breakup by Technology:
- Immunoassay
- Tandem Mass Spectroscopy
- Sensor Technology
- LC-MS
- Others
Breakup by End Use:
- Hospitals
- Ambulatory Care Centers
- Clinical Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc.Key Questions Answered in This Report:
- How has the global endocrine testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global endocrine testing market?
- What are the key regional markets?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global endocrine testing market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Endocrine Testing Market
6 Market Breakup by Test Type
7 Market Breakup by Technology
8 Market Breakup by End Use
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- BioMerieux SA
- DiaSorin S.p.A.
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Siemens Healthineers AG (Siemens Aktiengesellschaft)
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 139 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 11.2 Billion |
| Forecasted Market Value ( USD | $ 20.7 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
